Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Multi-center Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Subjects With Relapsed/Refractory Large B-Cell Lymphoma

NCT03704298 is registered in ClinicalTrials.gov with Kite, A Gilead Company as lead sponsor.

NCT NCT03704298
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03704298 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Multi-center Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Subjects With Relapsed/Refractory Large B-Cell Lymphoma
Lead sponsor
Kite, A Gilead Company
Phase
Phase 1
Overall status
Terminated
Start date
November 20, 2018
Completion date
December 15, 2022
Enrollment
15 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory large b-cell lymphoma